Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Jan 13, 2021

Provention Bio Announces Pricing of $100 Million Public Offering of Common Stock
Jan 12, 2021

Provention Bio Announces Proposed Public Offering of Common Stock
Jan 6, 2021

Provention Bio to Participate in the H.C. Wainwright Virtual BioConnect Conference
Jan 4, 2021

Provention Bio Announces U.S. FDA Filing of a Biologics License Application (BLA) and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals

-FDA sets PDUFA goal date of July 2, 2021-
Dec 21, 2020

Provention Bio Announces Addition to NASDAQ Biotechnology Index

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.